Cellular material containing living cells is preserved by combining the cellular material with a cryoprotectant formulation/medium/solution containing an effective amount of trehalose (in the absence of DMSO and/or any other added cryoprotectants) during a cryopreservation protocol. That is, the cryopreservation protocol is free of cryoprotectant other than trehalose, and the cryopreservation protocol includes: exposing the cellular material to a cryoprotectant formulation containing an effective amount of the trehalose to act as a cryoprotectant, cooling the cellular material at a cooling rate in the range of from −3° C./minute to −50° C./minute to a predetermined temperature below −20° C., and obtaining a cryopreserved cellular material that has been warmed.

A method for organ and tissue chimerization using bone marrow cellular treatment, which avoids rejection of transplanted organs and diminishes or suspends the use of immunosuppressant drugs in patients subjected to transplant procedures. The method comprises washing the organ in an electrolyte solution. A further step of washing the organ in a wash solution. The organ is then placed in a culture solution and incubated with bone marrow cells.

A device for controllable growth of ice crystals inside an organic object during freezing, the device comprising at least one transducer, a control unit, a power supply and a modulator, wherein the control unit causes a plurality of types of magnetic fields to be emitted, by the at least one transducer, in a cyclical manner, and the control unit determines, for each type of magnetic field comprised in the plurality of types of magnetic fields, a carrier frequency, a modulation frequency, modulation boundaries and duty cycle, and sets them by utilizing the signal generator and the power supply; and wherein a strength of the plurality of the types of the magnetic fields is determined by adjusting an output voltage provided by the power supply.

The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

The present invention relates to methods of cryopreservation and compositions for use in such methods where the methods utilise non-Newtonian fluid properties of the cryopreservation medium to modulate the viscosity of that medium to deliver an improved cryopreservation process.

The present invention provides a method for evaluating effectiveness of a cell therapeutic agent. When using TGF-β and/or TSP-1 expression level(s) in: (a) a first population of transformed mammalian cells with TGF-β; and (b) a second population of untransformed mammalian cells with the same gene, respectively, as a criterion for determining effectiveness of a cell therapeutic agent, and whether or not expression thereof, it is possible to definitely determine the therapeutic efficacy of each cell therapeutic agent prior to initiation of the treatment. In addition, since use of a cell therapeutic agent without therapeutic effects is avoided, undesired procedures and side effects may not be entailed.

A thermal capacitor includes a shell and a PCM. The shell includes a first major surface that is configured to contact a container including media to be frozen. The shell defines a cavity in which the PCM is disposed. The PCM has a transition temperature in a range of −80 degrees Celsius to −50 degrees Celsius and is configured to rapidly freeze media from room temperature to −60 degrees Celsius with the container including the media in contact with the shell in an enclosed space.

A carrier for receiving a vessel includes a body that defines a well. The well is sized and dimensioned to receive a vessel including media. The body is configured to urge the vessel received in the well towards an external wall of the body to enhance thermal energy transfer into or out of the media within the vessel. A box assembly for supporting media during thermal changes includes a box, a vessel, and a carrier is also disclosed.

The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.

Disclosed are compounds and compositions for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. Also disclosed herein are methods for storing platelets and methods for improving platelet survival upon transfusion with one or more compounds or compositions as described herein.